How Has the Severe Acute Respiratory Syndrome Treatment Market Evolved Historically and What is its Current Size?
The severe acute respiratory syndrome treatment market has seen considerable growth due to a variety of factors.
• The market size for severe acute respiratory syndrome treatment has experienced significant expansion in the past few years. Its size is projected to rise from $3.45 billion in 2024 to $3.97 billion in 2025, marking a compound annual growth rate (CAGR) of 15.2%.
The growth observed in the historic period can be credited to responses to global outbreaks, the development of antiviral drugs and vaccines, and efforts towards public health readiness.
What Is The Projected Growth Of The Severe Acute Respiratory Syndrome Treatment Template Market?
The severe acute respiratory syndrome treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for significant expansion in the severe acute respiratory-syndrome treatment market in the coming years, with projections suggesting a rise to $7.15 billion by 2029. This would equate to a compound annual growth rate (CAGR) of 15.8%.
The anticipated growth during this forecast period is largely attributed to contributions from broad-spectrum antivirals, emerging therapeutics, vaccine advancements, and pandemic preparedness. Noteworthy trends expected to feature during this period include RNA-targeted therapies, the application of AI in drug discovery, global collaborations and efforts towards public health education.
What Are The Key Drivers Fueling Growth In The Severe Acute Respiratory Syndrome Treatment Market?
The escalating prevalence of respiratory ailments is anticipated to fuel the expansion of the market for severe acute respiratory syndrome treatment. These conditions, which affect the respiratory system responsible for breathing and gas exchange with the environment, could lead to respiratory failure if not treated. The treatment of severe acute respiratory syndrome helps relieve symptoms, prevent respiratory failure, decrease inflammation, and maintain oxygen levels. To illustrate, the National Asthma Council, an Australian non-profit organization for asthma care improvement and management, reported a rise in asthma-related deaths from 355 in 2021 to 467 in 2022. Consequently, the increasing prevalence of respiratory diseases is propelling the market for severe acute respiratory syndrome treatment. The severe acute respiratory syndrome treatment market is set to grow as a result of increasing investments in research and development. R&D investments encompass the financial and human resources allocated by organizations, governments or entities for investigations and activities aimed at discovering new knowledge. Such investments are critical in enhancing treatment options for severe acute respiratory syndromes such as SARS and COVID-19 as they lead to the creation of effective drugs, vaccines, diagnostics, and therapeutic approaches. The U.S. Department of Health and Human Services, for instance, granted more than $1.4 billion in August 2023 towards Project NextGen with the aim of supporting the development of next-generation COVID-19 vaccines and treatments. Therefore, the growth of the market for severe acute respiratory syndrome treatment is being propelled by the increase in research and development investments.
What Are The Principal Market Segments In The Global Severe Acute Respiratory Syndrome Treatment Industry?
The severe acute respiratory-syndrome treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-
2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications
Pre-Book The Severe Acute Respiratory Syndrome Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Severe Acute Respiratory Syndrome Treatment Market?
Leading firms in the severe acute respiratory syndrome therapy market are introducing cutting-edge techniques like multiplexed real-time PCR to maintain their market standing. This molecular biology technology enables the enlargement and identification of several DNA or RNA targets in one single process. For example, TransGen Biotech Co. Ltd., a producer and researcher of molecular and cellular biology products based in Beijing, launched the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay in July 2022. This new assay is a multiplexed real-time PCR assay that allows the detection and distinction between SARS CoV 2, Influenza A, Influenza B, and respiratory syncytial virus (RSV) using just one specimen. In addition, this tool proves useful in diagnosing and treating SARS, influenza, and RSV, effectively aiding treatment decision and hindering disease propagation.
Who Are the Key Players In The Severe Acute Respiratory Syndrome Treatment Market?
Major companies operating in the severe acute respiratory-syndrome treatment market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Merck And Co Inc.
• Novartis AG
• Bristol Myers Squib company
• GlaxoSmithKline PLC
• AstraZeneca PLC
• Sanofi SA
• Eli Lilly And Company
• Gilead Sciences Inc.
• Amgen Inc.
• Johnson And Johnson Private Limited
• Moderna Inc.
• Regeneron Pharmaceuticals Inc.
• Hetero labs Ltd.
• Alexion Pharmaceuticals Inc.
• Cadila healthcare Ltd.
• Genentech Inc.
• Cipla Ltd.
• Biogen Inc.
• Vir Biotechnology Inc.
• Swedish Orphan Biovitrum AB
• Dynavax Technologies Corporation
• ViiV Healthcare Limited
• Panacea Biotec Limited
• CureVac N.V.
• CN Bio Innovations Ltd.
• Inovio Pharmaceuticals Inc.
• Chimerix Inc.
What Are The Regional Insights Into The Severe Acute Respiratory Syndrome Treatment Market?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
